Berinert P Study of Subcutaneous Versus Intravenous Administration
Completed
Clinical trial center Rhine-Main
Phase 3
2008-09-01
The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.)
administration of Berinert P in patients with hereditary angioedema (HAE) to establish a
second administration mode in cases where i.v. access is not suitable.
The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic
study.
Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert
P) and than switch to the treatment not administered before.
Berinert P Study of Subcutaneous Versus Intravenous Administration
Completed
CSL Behring
Phase 3
2008-09-01
The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.)
administration of Berinert P in patients with hereditary angioedema (HAE) to establish a
second administration mode in cases where i.v. access is not suitable.
The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic
study.
Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert
P) and than switch to the treatment not administered before.
Berinert P Study of Subcutaneous Versus Intravenous Administration
Completed
Institut für Medizinische Virologie JWG-University hospital
Phase 3
2008-09-01
The study is performed to investigate the subcutaneous (s.c.) versus intravenous (i.v.)
administration of Berinert P in patients with hereditary angioedema (HAE) to establish a
second administration mode in cases where i.v. access is not suitable.
The study is planned as a single centre, randomized, open-label, cross-over pharmacokinetic
study.
Subjects will either start with s.c. or i.v. pasteurised C1-Inhibitor concentrate (Berinert
P) and than switch to the treatment not administered before.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
